ARAY - Accuray Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.10
0.00 (0.00%)
At close: 4:00PM EDT

5.10 0.00 (0.00%)
After hours: 4:59PM EDT

Stock chart is not supported by your current browser
Previous Close5.10
Open5.10
Bid4.55 x 100
Ask5.30 x 1200
Day's Range5.05 - 5.15
52 Week Range3.60 - 6.15
Volume278,591
Avg. Volume747,425
Market Cap434.996M
Beta2.46
PE Ratio (TTM)N/A
EPS (TTM)-0.29
Earnings DateApr 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.20
Trade prices are not sourced from all markets
  • PR Newswire10 days ago

    Accuray to Bring Patient-First Cancer Treatment Innovations to ESTRO 37

    SUNNYVALE, Calif., April 17, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today it will be showcasing the benefits of its radiotherapy systems and software solutions at the 37th annual European Society for Radiotherapy and Oncology (ESTRO) meeting in Barcelona, Spain. The meeting, to be held April 20-24, 2018, will attract more than 3,000 radiation oncology professionals who will gather to gain information and insights on the latest developments in radiation therapy. Accuray will be in attendance at booth #1700, sharing information on new treatment approaches and providing opportunities for conversations about how the company's innovative CyberKnife® and Radixact® Systems, and advanced software solutions, can help improve the radiation therapy treatment experience for clinicians and their patients.

  • PR Newswire10 days ago

    Accuray to Bring Patient-First Cancer Treatment Innovations to ESTRO 37

    Accuray Incorporated (ARAY) announced today it will be showcasing the benefits of its radiotherapy systems and software solutions at the 37th annual European Society for Radiotherapy and Oncology (ESTRO) meeting in Barcelona, Spain. The meeting, to be held April 20-24, 2018, will attract more than 3,000 radiation oncology professionals who will gather to gain information and insights on the latest developments in radiation therapy. Accuray will be in attendance at booth #1700, sharing information on new treatment approaches and providing opportunities for conversations about how the company's innovative CyberKnife® and Radixact® Systems, and advanced software solutions, can help improve the radiation therapy treatment experience for clinicians and their patients.

  • PR Newswire18 days ago

    Accuray To Report Fiscal 2018 Third Quarter Financial Results On April 30, 2018

    SUNNYVALE, Calif. , April 9, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its third quarter ended March 31, 2018 on Monday, April 30, 2018 after the market close, following ...

  • Accuray Radixact Picked by India's Apollo for Cancer Treatment
    Zacks29 days ago

    Accuray Radixact Picked by India's Apollo for Cancer Treatment

    Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.

  • Accuray's CyberKnife Treats First Patient at Erasmus MC
    Zacks29 days ago

    Accuray's CyberKnife Treats First Patient at Erasmus MC

    Accuray (ARAY) and Erasmus MC partner to develop CyberKnife platform to simplify diagnosis of oligometastatic diseases.

  • Accuray Banks on Acquisition & Partnership Amid Competition
    Zackslast month

    Accuray Banks on Acquisition & Partnership Amid Competition

    Accuray's (ARAY) partnerships with Premier and Amerinet are expected to help the company gain significant penetration in hospitals and oncology centers.

  • PR Newswirelast month

    Apollo Hospitals in India to Acquire Two Accuray Radixact® Systems

    SUNNYVALE, Calif., March 28, 2018 /PRNewswire/ -- Personalized, precise, radiation treatments will soon be available to more cancer patients in India. Accuray Incorporated (ARAY) announced today that the company has signed an agreement with the Apollo Hospitals Group in Chennai and New Delhi, India, for the acquisition of two Radixact® Systems, radiation therapy devices that have been proven to deliver highly accurate treatments for a broad range of tumors anywhere in the body. The installation of these systems, one replacing a conventional linear accelerator and the other in a new vault, will expand access to state-of-the-art cancer treatment technology for the people of India.

  • PR Newswirelast month

    Erasmus MC Completes First Step in the Evolution of Online Adaptive Radiation Therapy with the CyberKnife® System

    SUNNYVALE, Calif. and ROTTERDAM, Netherlands, March 27, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) and Erasmus MC, the largest university medical center in the Netherlands, announced today that the first patient has been successfully treated using an online-adaptive (OA) approach together with the CyberKnife® System. The patient, treated for oligometastases in the pelvic region, is part of a new clinical trial conducted at Erasmus MC evaluating OA stereotactic body radiation therapy (SBRT) delivered by the CyberKnife platform. "At Erasmus MC our goal is to use innovative approaches to provide customized, effective treatments that help extend or improve the quality of life of people diagnosed with cancer, regardless of the stage of their cancer diagnosis," said J.J. Nuyttens, MD, PhD, radiation oncologist, department of radiation oncology, Erasmus MC.

  • Accuray Gains on Radixact Unit, Solid Geographical Foothold
    Zackslast month

    Accuray Gains on Radixact Unit, Solid Geographical Foothold

    Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).

  • Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session
    Zackslast month

    Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session

    The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.

  • How Accuray Has Performed Financially
    Market Realist2 months ago

    How Accuray Has Performed Financially

    In 2Q18, Accuray’s (ARAY) net revenues were $100.3 million compared with $87.5 million in 2Q17. Its total revenues come from product sales and services provided. Product sales grew from $35.3 million in 2Q17 to $47.1 million in 2Q18.

  • How Much Is Accuray’s Target Market Expected to Grow?
    Market Realist2 months ago

    How Much Is Accuray’s Target Market Expected to Grow?

    To increase physician adoption and patient awareness of its systems, Accuray (ARAY) holds and sponsors symposia and educational meetings and educates clinicians about its systems. Accuray focuses on innovation through clinical development and collaboration and seeks constructive feedback from its system users to enhance the company’s product offerings. Accuray endeavors to expand sales in international markets. According to the World Health Organization (or WHO), cancer is the second-leading cause of death worldwide.

  • What Analysts Recommend for Accuray in February 2018
    Market Realist2 months ago

    What Analysts Recommend for Accuray in February 2018

    Accuray (ARAY) designs, develops, and commercializes advanced radiosurgery and radiation therapy systems for the treatment of tumors. Accuray’s technologies include the CyberKnife and Tomo Theory systems, which deliver radiosurgery, stereotactic body radiation therapy, and adaptive radiation therapy. In February 2018, three of the seven analysts covering Accuray have given the stock a “buy” or higher rating.

  • A Look at Accuray’s Therapy Systems
    Market Realist2 months ago

    A Look at Accuray’s Therapy Systems

    Accuray’s (ARAY) CyberKnife systems are robotic systems that treat cancerous tumors through the delivery of radiosurgery. Accuray’s Tomo therapy systems are versatile radiation therapy systems that are used for treating a wide range of cancer types. Based on a CT scanner platform, the Tomo therapy systems provide continuous delivery of radiation from 360 degrees around the patient or from beam angles specified by the clinician.

  • Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?
    Zacks2 months ago

    Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?

    Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • PR Newswire2 months ago

    Accuray to Present at the 2018 RBC Capital Markets Global Healthcare Conference on February 22, 2018

    SUNNYVALE, Calif. , Feb. 15, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will present at the 2018 RBC Capital Markets Global Healthcare Conference at the Lotte ...

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Accuray, Carlisle Companies, Greenhill & Co., Timken, HomeTrust Bancshares, and Inphi — Future Expectations, Projections Moving into 2018

    NEW YORK, Feb. 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Accuray ...

  • AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up
    Zacks3 months ago

    AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up

    Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.

  • Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid
    Zacks3 months ago

    Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid

    Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.

  • athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4
    Zacks3 months ago

    athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4

    Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.

  • PR Newswire3 months ago

    Accuray Retires February 2018 Convertible Notes

    SUNNYVALE, Calif., Feb. 5, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today it has retired all February 2018 convertible notes, including $13 million aggregate principal amount of its 3.50% convertible senior notes and $27 million aggregate principal amount of its 3.50% Series A convertible senior notes both due February 1, 2018. Accuray successfully entered into exchange agreements with the holders of the 3.50% convertible senior notes allowing the Company to settle the $13 million outstanding principal amount and accrued interest in cash and approximately 0.3 million shares of its common stock.  After giving effect to the settlement of the exchange agreements, no 3.50% convertible senior notes will remain outstanding.

  • Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
    Zacks3 months ago

    Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up

    Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.

  • Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong
    Zacks3 months ago

    Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong

    Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.

  • Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top
    Zacks3 months ago

    Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top

    In Q4, Boston Scientific (BSX) registers balanced growth across all business lines and geographies.

  • Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4
    Zacks3 months ago

    Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4

    Conmed (CNMD) benefits from impressive general surgery performance and enhanced innovation in Q4.